EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Type II diabetes mellutis with amylin agonists



Treatment of Type II diabetes mellutis with amylin agonists



Official Gazette of the United States Patent & Trademark Office Patents 1240(1), Nov 7



Methods for treating non-insulin-taking Type II diabetes mellitus which comprise administering a therapeutically effective amount of an amylin agonist.

(PDF 0-2 workdays service: $29.90)

Accession: 035980643

Download citation: RISBibTeXText



Related references

Treatment of type II diabetes mellitus with amylin agonists. Official Gazette of the United States Patent & Trademark Office Patents 1260(2), July 9, 2002

Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53 Suppl 3: S233-S238, 2004

New treatments of diabetes: the beta-amylin agonists. Annales D'endocrinologie 69(2): 147-150, 2008

Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus. Expert Opinion on Investigational Drugs 10(9): 1641-1652, 2002

Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group. Diabetes Care 21(6): 987-993, 1998

The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus. Hormone and Metabolic Research 31(8): 472-475, 1999

GPR119 agonists for the treatment of type 2 diabetes. Expert Opinion on Therapeutic Patents 19(10): 1339-1359, 2010

Treatment of type 2 diabetes mellitus with GLP-1 agonists. Vnitrni Lekarstvi 57(4): 411-415, 2011

S20G mutation of the amylin gene is associated with Type II diabetes in Japanese. Study Group of Comprehensive Analysis of Genetic Factors in Diabetes Mellitus. Diabetologia 44(7): 906-909, 2001

Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus. Current Diabetes Reports 12(5): 560-567, 2013

A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. Expert Opinion on PharmacoTherapy 13(10): 1451-1467, 2012

Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?. Diabetes Technology & Therapeutics 18(11): 671-673, 2016

What can be expected from the GLP-1 agonists and DPP-4 inhibitors in the treatment of type 2 diabetes?. Revue Medicale Suisse 3(114): 1449-50, 1453-5, 2007

Selective PPAR agonists for the treatment of type 2 diabetes. Annals of the New York Academy of Sciences 1067: 448-453, 2006

GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Hormone and Metabolic Research 36(11-12): 867-876, 2005